William E. Fisher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
William E. Fisher has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Felipe Amaya
Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas, USA
2 shared publicationsDan Reichenbach
Baylor Coll Med, Elkins Pancreas Ctr, Michael E DeBakey Dept Surg, Houston, TX 77030 USA
1 shared publicationDavid H. Berger
1 shared publicationDiego Camacho
The Elkins Pancreas Center, Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas, USA
1 shared publicationE. Graviss
Department of Pathology, Baylor College of Medicine, 209E One Baylor Plaza, Houston, TX 77030, USA
1 shared publicationF. Essien
Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Smith Tower, 6550 Fannin, Suite 1661, Houston, TX 77030, USA
1 shared publication
Latest Publications
- 1 November 2005
- Vol. 6 (6) , 552-561
Value of Laparoscopy in the Staging of Pancreatic Cancer
Pancreatic cancer is a devastating disease that swiftly robs patients of both quality and quantity of life. It is the fourth leading cause of cancer death in the United States. In 2003, there were 31,860 reported new cases with 31,270 deaths occurring due to lack of effective therapy. Eighty percent of patients present with either advanced local or metastatic disease. Dynamic contrast-enhanced computed tomography (CT) has become the current staging test of choice. Laparoscopic staging of pancreatic tumors with the addition of ultrasound can reveal intraparenchymal hepatic metastases, small peritoneal metastases, and critical retroperitoneal tumor-vessel relationships approaching the accuracy of open exploration to determine resectability without significantly increasing morbidity or mortality. However, given the current accuracy of high-quality CT, the routine use of diagnostic laparoscopy in pancreatic cancer is not warranted. Diagnostic laparoscopy is recommended in select patients with primary tumors greater than 4 cm, tumors in the body or tail of the pancreas, patients with equivocal findings of metastasis on CT, ascites, or clinical or laboratory findings suggesting advanced disease such as marked weight loss, hypoalbuminemia, and elevated CA 19-9.
- 1 November 2005
- Vol. 6 (6) , 552-561
Value of Laparoscopy in the Staging of Pancreatic Cancer
Pancreatic cancer is a devastating disease that swiftly robs patients of both quality and quantity of life. It is the fourth leading cause of cancer death in the United States. In 2003, there were 31,860 reported new cases with 31,270 deaths occurring due to lack of effective therapy. Eighty percent of patients present with either advanced local or metastatic disease. Dynamic contrast-enhanced computed tomography (CT) has become the current staging test of choice. Laparoscopic staging of pancreatic tumors with the addition of ultrasound can reveal intraparenchymal hepatic metastases, small peritoneal metastases, and critical retroperitoneal tumor-vessel relationships approaching the accuracy of open exploration to determine resectability without significantly increasing morbidity or mortality. However, given the current accuracy of high-quality CT, the routine use of diagnostic laparoscopy in pancreatic cancer is not warranted. Diagnostic laparoscopy is recommended in select patients with primary tumors greater than 4 cm, tumors in the body or tail of the pancreas, patients with equivocal findings of metastasis on CT, ascites, or clinical or laboratory findings suggesting advanced disease such as marked weight loss, hypoalbuminemia, and elevated CA 19-9.
- 1 October 2005
- Published by Elsevier in Journal of Surgical Research
- Vol. 128 (2) , 162-164
Abstract Writing
- 1 October 2005
- Published by Elsevier in Journal of Surgical Research
- Vol. 128 (2) , 162-164
Abstract Writing
- 30 November 2003
- Published by Elsevier in Journal of Surgical Research
- Vol. 115 (1) , 41-47
Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts
- 30 November 2003
- Published by Elsevier in Journal of Surgical Research
- Vol. 115 (1) , 41-47
Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts
- 1 December 2002
- Published by Springer Nature in Hernia
- Vol. 6 (4) , 182-187
Laparoscopic ventral hernia repair during the learning curve
Large series of laparoscopic ventral hernia repair have shown excellent results. However, published comparative studies have had conflicting outcomes. We retrospectively reviewed the first 29 laparoscopic ventral hernia repairs performed at a VA Medical Center from January 2000 to June 2001. The outcome was compared to that of open repairs performed during the same time period. Outcomes between the groups were similar in all respects, except for the length of stay. The conversion rate for the laparoscopic approach was 13.8%. There was one death in the laparoscopic group due to an unrecognized enterotomy. There were three recurrences in the open group and one in the laparoscopic group with a mean follow up of 13 months. In our series, laparoscopic hernia repair resulted in a shorter hospital stay but no other significant benefits, along with a risk of missed enterotomy. The risk-benefit ratio for this procedure may be high during the learning curve.
- 1 December 2002
- Published by Springer Nature in Hernia
- Vol. 6 (4) , 182-187
Laparoscopic ventral hernia repair during the learning curve
Large series of laparoscopic ventral hernia repair have shown excellent results. However, published comparative studies have had conflicting outcomes. We retrospectively reviewed the first 29 laparoscopic ventral hernia repairs performed at a VA Medical Center from January 2000 to June 2001. The outcome was compared to that of open repairs performed during the same time period. Outcomes between the groups were similar in all respects, except for the length of stay. The conversion rate for the laparoscopic approach was 13.8%. There was one death in the laparoscopic group due to an unrecognized enterotomy. There were three recurrences in the open group and one in the laparoscopic group with a mean follow up of 13 months. In our series, laparoscopic hernia repair resulted in a shorter hospital stay but no other significant benefits, along with a risk of missed enterotomy. The risk-benefit ratio for this procedure may be high during the learning curve.
- 1 June 2002
- Published by Elsevier in Journal of Surgical Research
- Vol. 105 (1) , 58-64
Somatostatin Receptor Subtype 2 Gene Therapy Inhibits Pancreatic Cancer in Vitro
- 1 June 2002
- Published by Elsevier in Journal of Surgical Research
- Vol. 105 (1) , 58-64
Somatostatin Receptor Subtype 2 Gene Therapy Inhibits Pancreatic Cancer in Vitro